Product/Composition:- | Romiplostim injection |
---|---|
Strength:- | 250mcg/vial, 500 mcg/vial |
Form:- | Injection |
Reference Brands:- | Nplate®(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Romiplostim is a thrombopoietin receptor agonist that stimulates platelet production by activating the TPO receptor on megakaryocytes. It increases platelet counts, reducing bleeding risk in chronic immune thrombocytopenic purpura (ITP). Benefits include improved blood cell counts, decreased bleeding episodes, and enhanced quality of life for patients with thrombocytopenia.
Romiplostim injection, marketed as Nplate®, is approved by the FDA and EMA for treating chronic immune thrombocytopenic purpura (ITP). Regulatory dossiers include comprehensive clinical trial data, manufacturing standards, and safety profiles, ensuring high-quality product approval. The dossiers support its efficacy in increasing platelet counts and reducing bleeding risk. Nplate® is administered as a subcutaneous injection, with dosing tailored to patient needs. For detailed information on regulatory processes, dossier submissions, and market approvals in the EU and US, visit PharmaTradz, your trusted source for pharmaceutical regulatory insights and industry updates.